Table 4.

Antibody blocking of the CD8 anti-Vβ8 T hybridoma responses

		Response to stimulators
		LBRM positive control	4G4Vβ8 negative control	LBRM with blocking antibody						1AE10 positive control	3AF9 negative control	1AE10 with blocking antibody
Exp.	T cell hybridoma			Anti-Qa-1a	Anti-Qa-1b	M1/42	Rat Ig	16-1-2N	Y3P			AntiQa-1a	Anti-Qa-1b	M1/42	Rat Ig	3-83P	Y3P
1	21-5A9	0.618	0.051	0.023	0.637	0.637	0.660	0.502	0.629	0.389	0.004	0.160	0.406	0.314	0.411	0.294	0.382
		(—)	(—)	(99.6)*	(0)	(0)	(0)	(18.7)	(0)	(—)	(—)	(58.9)	(0)	(19.3)	(0)	(24.2)	(0)
2	21-5A9	0.751	0.037	0.014	0.758	0.774	0.790	0.636	0.759	0.435	NT	0.206	0.552	0.495	0.558	0.444	0.547
		(—)	(—)	(98.1)	(0)	(0)	(0)	(15.3)	(0)	(—)		(52.6)	(0)	(0)	(0)	(2.1)	(0)
3	176-5F7	0.781	0.058	0.055	0.812	0.830	0.857	0.656	0.774	0.375	NT	0.032	0.267	0.339	0.344	0.279	0.547
		(—)	(—)	(92.9)	(0)	(0)	(0)	(16.0)	(4.7)	(—)		(91.5)	(28.8)	(9.6)	(8.3)	(25.6)	(0)

Anti-Qa-1^a and Qa-1^b antisera (13) were used at a 1:100 final dilution. The mAbs (M1/42, rat IgG anti-mouse MHC class I-a; 16-1-2N, mouse IgG2a anti-H-2K^kD^k; 3-83P, mouse IgG2a, anti-H-2^k, crossreactive with H-2^u; Y3P, control mouse IgG2a anti-I-A^b) and purified rat Ig were used at a final concentration of 20 μg/ml except for the 16-1-2N antibody, which was used as supernatant at 1:4 final dilution. Results are expressed as means of triplicates as in Table 3. NT, not tested. 

^*Anti-Qa-1^a antiserum did not inhibit phorbol 12,13-dibutyrate/ionomycin stimulation of hybridoma cells. Percent inhibition is indicated in parentheses where applicable and was calculated as [(positive control − experimental)/positive control] × 100%.